Overview
2012Founded1
Compare with Natural Alternatives International, MARIMED INC. or Niagen Bioscience, Inc., or pick any stock.
- TickerCRON on Nasdaq1
- Industryhealth care1
- HeadquartersToronto, Canada1
- Websitethecronosgroup.com
- Incorporated inBritish Columbia, Canada4
- Business address4491 Concession Rd 12, Stayner, A6 L0M 1S04
- Filer categoryAccelerated filer4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
42.8%Gross margin5
-11.9%Operating margin5
-6.4%Net margin5
24.6%Revenue growth, 20255
-0.9%Return on equity5
$149.0KFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Cannabis Flower brought in 74% of the revenue Cronos Group Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cannabis Flower | $62.1M | $87.9M | $108.5M |
| Cannabis Extracts | $24.6M | $29.2M | $37.7M |
| Product and Service, Other | $602.0K | $535.0K | $411.0K |
Regions
Canada brought in 62% of the revenue Cronos Group Inc broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Canada | $64.7M | $82.4M | $90.3M |
| Israel | $21.1M | $28.4M | $41.8M |
| Other Countries | $1.4M | $6.8M | $14.5M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development3¢$4.4M
- Other costs87¢$127.9M
- Income tax10¢$14.2M
Out of $146.6M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending73¢$25.7M
- Share buybacks27¢$9.7M
Out of $25.9M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net revenue, before excise taxes | $193.4M | $161.8M | $120.3M |
| Excise taxes | -$46.8M | -$44.2M | -$33.0M |
| Net revenue | $146.6M | $117.6M | $87.2M |
| Cost of sales | $83.2M | $91.7M | $74.5M |
| Inventory write-down | $654.0K | $707.0K | $805.0K |
| Gross profit | $62.8M | $25.2M | $11.9M |
| Sales and marketing | $21.8M | $21.6M | $22.7M |
| Research and development | $4.4M | $4.2M | $5.8M |
| General and administrative | $42.0M | $46.5M | $49.5M |
| Restructuring costs | $2.0M | $630.0K | $1.5M |
| Share-based compensation | $7.0M | $8.7M | $8.8M |
| Depreciation and amortization | $2.1M | $3.7M | $5.0M |
| Impairment loss on goodwill and indefinite-lived intangible assets | $700.0K | $0 | $0 |
| Impairment loss on long-lived assets | $36.0K | $16.4M | $3.4M |
| Total operating expenses | $80.2M | $101.7M | $96.7M |
| Operating loss | -$17.4M | -$76.5M | -$84.8M |
| Interest income, net | $40.0M | $52.0M | $51.2M |
| Share of income from equity method investments | $0 | $2.4M | $1.6M |
| Gain on revaluation of loan receivable | $0 | $11.8M | $0 |
| Gain on revaluation of equity method investment | $0 | $32.5M | $0 |
| Loss on revaluation of financial instruments | -$452.0K | -$6.2M | -$12.0M |
| Impairment loss on other investments | $0 | -$25.6M | -$23.4M |
| Foreign currency transaction gain (loss) | -$28.6M | $57.9M | -$7.3M |
| Loss on held-for-sale assets | -$5.5M | -$11.2M | $0 |
| Change in allowance for credit loss on non-operating loan | -$4.9M | $0 | $0 |
| Other, net | -$241.0K | -$301.0K | $1.0M |
| Total other income | $275.0K | $113.1M | $11.1M |
| Income (loss) before income taxes | -$17.1M | $36.6M | -$73.7M |
| Income tax benefit | -$14.2M | -$3.4M | -$3.2M |
| Income (loss) from continuing operations | -$2.9M | $40.0M | -$70.4M |
| Loss from discontinued operations | $0 | $0 | -$4.1M |
| Net income (loss) | -$2.9M | $40.0M | -$74.6M |
| Net income (loss) attributable to non-controlling interest | $6.5M | -$1.1M | -$590.0K |
| Net income (loss) attributable to Cronos Group | -$9.4M | $41.1M | -$74.0M |
| Foreign exchange gain (loss) on translation | $48.7M | -$86.3M | $21.5M |
| Comprehensive income (loss) | $45.8M | -$46.3M | -$53.0M |
| Comprehensive income (loss) attributable to non-controlling interest | $8.6M | -$3.2M | -$526.0K |
| Comprehensive income (loss) attributable to Cronos Group | $37.2M | -$43.1M | -$52.5M |
| Basic - continuing operations (in dollars per share) | -$0 | $0 | -$0 |
| Basic - discontinued operations (in dollars per share) | $0 | $0 | -$0 |
| Basic net income (loss) per share attributable to Cronos Group (in dollars per share) | -$0.02 | $0.11 | -$0.19 |
| Diluted - continuing operations (in dollars per share) | -$0 | $0 | -$0 |
| Diluted - discontinued operations (in dollars per share) | $0 | $0 | -$0 |
| Diluted net income (loss) per share attributable to Cronos Group (in dollars per share) | -$0.02 | $0.11 | -$0.19 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $791.8M | $858.8M | ||
| Short-term investments | $40.0M | $0 | ||
| Accounts receivable, net | $34.1M | $15.5M | ||
| Interest receivable | $8.7M | $8.7M | ||
| Other receivables | $14.4M | $5.0M | ||
| Current portion of loans receivable, net | $0 | $618.0K | ||
| Inventory, net | $46.8M | $33.1M | ||
| Prepaids and other current assets | $8.3M | $6.3M | ||
| Held-for-sale assets | $0 | $8.1M | ||
| Total current assets | $944.1M | $936.1M | ||
| Other investments | $7.7M | $2.8M | ||
| Non-current portion of loans receivable, net | $20.8M | $15.5M | ||
| Property, plant and equipment, net | $145.9M | $133.2M | ||
| Right-of-use assets | $1.4M | $1.4M | ||
| Goodwill | $66.5M | $63.5M | ||
| Intangible assets, net | $8.9M | $11.3M | ||
| Deferred tax assets | $1.9M | $2.6M | ||
| Total assets | $1.2B | $1.2B | ||
| Accounts payable | $11.6M | $17.0M | ||
| Income taxes payable | $0 | $9.0K | ||
| Accrued liabilities | $36.2M | $31.7M | ||
| Current portion of lease obligation | $337.0K | $1.0M | ||
| Derivative liabilities | $0 | $40.0K | ||
| Total current liabilities | $48.2M | $49.7M | ||
| Non-current portion due to non-controlling interests | $733.0K | $1.1M | ||
| Non-current portion of lease obligation | $1.2M | $993.0K | ||
| Deferred tax liabilities | $4.1M | $3.6M | ||
| Total liabilities | $54.2M | $55.3M | ||
| Share capital and additional paid-in capital (no par value; authorized for issue as of December 31, 2025 and 2024: unlimited; shares outstanding as of December 31, 2025 and 2024: 381,592,969 and 382,530,780, respectively) | $663.0M | $669.9M | ||
| Retained earnings | $447.8M | $457.7M | ||
| Accumulated other comprehensive loss | -$16.8M | -$63.5M | ||
| Total equity attributable to shareholders of Cronos Group | $1.1B | $1.1B | ||
| Non-controlling interests | $49.1M | $46.9M | ||
| Total shareholders equity | $1.1B | $1.1B | $1.1B | $1.1B |
| Total liabilities and shareholders equity | $1.2B | $1.2B | ||
| Common stock, shares issued (in shares) | 381.6M shares | 382.5M shares | ||
| Common stock, shares outstanding (in shares) | 381.6M shares | 382.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $791.8M | $858.8M | ||
| Short-term investments | $40.0M | $0 | ||
| Accounts receivable, net | $34.1M | $15.5M | ||
| Interest receivable | $8.7M | $8.7M | ||
| Other receivables | $14.4M | $5.0M | ||
| Current portion of loans receivable, net | $0 | $618.0K | ||
| Inventory, net | $46.8M | $33.1M | ||
| Prepaids and other current assets | $8.3M | $6.3M | ||
| Held-for-sale assets | $0 | $8.1M | ||
| Total current assets | $944.1M | $936.1M | ||
| Other investments | $7.7M | $2.8M | ||
| Non-current portion of loans receivable, net | $20.8M | $15.5M | ||
| Property, plant and equipment, net | $145.9M | $133.2M | ||
| Right-of-use assets | $1.4M | $1.4M | ||
| Goodwill | $66.5M | $63.5M | ||
| Intangible assets, net | $8.9M | $11.3M | ||
| Deferred tax assets | $1.9M | $2.6M | ||
| Total assets | $1.2B | $1.2B | ||
| Accounts payable | $11.6M | $17.0M | ||
| Income taxes payable | $0 | $9.0K | ||
| Accrued liabilities | $36.2M | $31.7M | ||
| Current portion of lease obligation | $337.0K | $1.0M | ||
| Derivative liabilities | $0 | $40.0K | ||
| Total current liabilities | $48.2M | $49.7M | ||
| Non-current portion due to non-controlling interests | $733.0K | $1.1M | ||
| Non-current portion of lease obligation | $1.2M | $993.0K | ||
| Deferred tax liabilities | $4.1M | $3.6M | ||
| Total liabilities | $54.2M | $55.3M | ||
| Share capital and additional paid-in capital (no par value; authorized for issue as of December 31, 2025 and 2024: unlimited; shares outstanding as of December 31, 2025 and 2024: 381,592,969 and 382,530,780, respectively) | $663.0M | $669.9M | ||
| Retained earnings | $447.8M | $457.7M | ||
| Accumulated other comprehensive loss | -$16.8M | -$63.5M | ||
| Total equity attributable to shareholders of Cronos Group | $1.1B | $1.1B | ||
| Non-controlling interests | $49.1M | $46.9M | ||
| Total shareholders equity | $1.1B | $1.1B | $1.1B | $1.1B |
| Total liabilities and shareholders equity | $1.2B | $1.2B | ||
| Common stock, shares issued (in shares) | 381.6M shares | 382.5M shares | ||
| Common stock, shares outstanding (in shares) | 381.6M shares | 382.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | -$2.9M | $40.0M | -$74.6M |
| Share-based compensation | $7.0M | $8.7M | $8.8M |
| Depreciation and amortization | $14.2M | $9.3M | $8.1M |
| Impairment loss on goodwill and indefinite-lived intangible assets | $700.0K | $0 | $0 |
| Impairment loss on long-lived assets | $36.0K | $16.4M | $3.6M |
| Impairment loss on other investments | $0 | $25.6M | $23.4M |
| Loss from investments | $446.0K | $3.8M | $10.5M |
| Changes in expected credit losses on long-term financial assets | $4.9M | $1.0M | -$1.5M |
| Revaluation of equity method investment | $0 | -$32.5M | $0 |
| Revaluation of loan receivable | $0 | -$11.8M | $0 |
| Loss on held-for-sale assets | $5.5M | $11.2M | $0 |
| Inventory step-up recorded to cost of sales | $517.0K | $5.3M | $0 |
| Foreign currency (gain) loss | $28.6M | -$57.9M | $7.3M |
| Other non-cash operating activities, net | $1.2M | -$131.0K | -$1.9M |
| Accounts receivable, net | -$16.7M | -$917.0K | $9.2M |
| Interest receivable | -$11.0K | -$3.7M | -$14.3M |
| Other receivables | -$9.0M | $2.1M | -$1.4M |
| Prepaids and other current assets | -$1.8M | -$512.0K | $1.4M |
| Inventory, net | -$10.4M | $7.4M | $7.4M |
| Accounts payable | $1.1M | -$7.4M | -$773.0K |
| Income taxes payable | -$10.0K | -$93.0K | -$33.1M |
| Accrued liabilities | $2.4M | $2.8M | $5.2M |
| Net cash provided by (used in) operating activities | $25.9M | $18.8M | -$42.8M |
| Purchase of short-term investments | -$40.0M | $0 | -$608.2M |
| Proceeds from short-term investments | $0 | $185.8M | $532.8M |
| Purchase of other investments | -$5.1M | $0 | $0 |
| Proceeds from sale of held for sale assets | $2.8M | $0 | $0 |
| Cash acquired in business combination | $0 | $6.0M | $0 |
| Advances on loans receivable | -$13.3M | -$8.8M | $0 |
| Proceeds from repayment on loans receivable | $5.1M | $5.3M | $16.8M |
| Dividends received from equity method investment | $0 | $0 | $1.3M |
| Dividend proceeds | $0 | $0 | $345.0K |
| Purchase of property, plant and equipment | -$25.7M | -$12.4M | -$2.5M |
| Purchase of intangible assets, net of disposals | -$339.0K | -$743.0K | -$918.0K |
| Other investing activities | $0 | $0 | $860.0K |
| Net cash provided by (used in) investing activities | -$76.6M | $175.1M | -$59.5M |
| Repurchases of common stock | -$9.7M | $0 | $0 |
| Dividend paid to non-controlling interest | -$6.4M | $0 | $0 |
| Withholding taxes paid on share-based awards | -$3.8M | -$1.2M | -$1.0M |
| Net cash used in financing activities | -$19.9M | -$1.2M | -$1.0M |
| Effect of foreign currency translation on cash and cash equivalents | $3.6M | -$3.2M | $8.0M |
| Net change in cash and cash equivalents | -$67.0M | $189.5M | -$95.4M |
| Interest paid | $0 | $0 | $0 |
| Interest received | $39.1M | $48.4M | $36.5M |
| Income taxes paid | $104.0K | $647.0K | $33.0M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Cronos Group Inc, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
201520202025
- Chief executive officerMichael Gorenstein1
- ChairMichael Gorenstein Sep 16, 2020 to Mar 18, 202213
- Chief financial officerJames Holm Nov 14, 2022 to now14
- Chief financial officerRobert L. Madore Aug 11, 2021 to Aug 11, 202215
- Chief financial officerJerry Filomena Barbato Dec 31, 2019 to Dec 31, 201916
Board members and other officers (30)
- OfficerJared Matthew Kenost Feb 26, 2026 to now17
- VP, ControllerLloyd Anderson Wilson Aug 11, 2025 to now18
- SVP, Head of Cronos IsraelAdam Wagner Apr 10, 2024 to now19
- VP, ControllerJames Andrew McGinness Iii. Jun 1, 2023 to now20
- OfficerJohn Griese Jan 12, 2022 to Mar 17, 202221
- General Manager (Israel)Ran Gorelik Apr 28, 2022 to Mar 19, 202422
- OfficerTerrence Gregory Joseph Doucet Apr 28, 2022 to now23
- OfficerArye Weigensberg Aug 18, 2022 to now24
- VP, ControllerCarlos S. Cortez Jun 23, 2021 to Mar 21, 202325
- SVP, Corporate AffairsAnna Shlimak Mar 2, 2020 to now26
- General Manager, USASummer Frein Aug 4, 2020 to Mar 4, 202227
- OfficerKurt Schmidt Sep 10, 2020 to Mar 4, 202228
- SVP, Global Head of PeopleShannon Buggy Nov 10, 2020 to now29
- OfficerJeffrey David Jacobson Dec 31, 2019 to now30
- OfficerMichael Gorenstein Dec 31, 2019 to now31
- Vice President & ControllerPuneet Mathur Dec 31, 2019 to May 13, 202132
- OfficerRobert Steven Rosenheck Dec 31, 2019 to Dec 31, 201933
- OfficerXiu Ming Shum Dec 31, 2019 to Nov 15, 202134
- Board memberDarren Chester Broughton Jun 30, 2026 to now35
- Board memberDominik Meier Jun 30, 2023 to Jun 30, 202336
- Board memberElizabeth Seegar Jun 30, 2023 to Jun 30, 202337
- Board memberKendrick Foster Ashton Jr. Jul 6, 2021 to Aug 10, 202338
- Board memberHeather A. Newman Mar 27, 2020 to Mar 27, 202039
- Board memberBronwen Christine Evans Dec 31, 2019 to Aug 11, 202040
- Board memberBruce Allen Gates Dec 31, 2019 to Dec 31, 201941
- Board memberJames Daniel Rudyk Dec 31, 2019 to now42
- Board memberJason Marc Adler Dec 31, 2019 to now43
- Board memberJody L. Begley Dec 31, 2019 to Dec 31, 201944
- Board memberMichael Gorenstein Dec 31, 2019 to now31
- Board memberMurray R. Garnick Dec 31, 2019 to now45
Former names
- PharmaCan Capital Corp.Oct 23, 2015 to May 27, 20164
Timeline
- 2012Founded Founded1
Filings
296 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 51 major events, 204 insider forms, 2 large holders, 18 other. The latest 20:
- Oct 15, 20268-K EDGAR
- Sep 11, 20268-K EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20268-K/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jun 30, 20263 EDGAR
- Jun 22, 20268-K EDGAR
- May 29, 2026SD EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 14, 20264 EDGAR
- May 12, 20264 EDGAR
- May 12, 20264 EDGAR
- May 12, 20264 EDGAR
- May 11, 202610-Q EDGAR
- May 11, 20268-K EDGAR
The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 2 such filings since October 2021:
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Feb 12, 2021 | John A. Yarmuth, House | Buy | $1,001 - $15,000 | −170.4% | Report |
| Nov 5, 2020 | John A. Yarmuth, House | Buy | $1,001 - $15,000 | −170.7% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Links
- Websitethecronosgroup.com1
- LinkedInwww.linkedin.com/company/cronos-group1
- WikidataQ75256038
- SEC EDGARCIK 1656472
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCronos Group Inc on Wikidata
- 2
- 3Company websiteCronos Group Inc logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARMichael Gorenstein, Chair
- 14SEC EDGARJames Holm, Chief financial officer
- 15
- 16
- 17SEC EDGARJared Matthew Kenost, Officer
- 18
- 19
- 20
- 21SEC EDGARJohn Griese, Officer
- 22
- 23
- 24SEC EDGARArye Weigensberg, Officer
- 25SEC EDGARCarlos S. Cortez, VP, Controller
- 26SEC EDGARAnna Shlimak, SVP, Corporate Affairs
- 27SEC EDGARSummer Frein, General Manager, USA
- 28SEC EDGARKurt Schmidt, Officer
- 29
- 30SEC EDGARJeffrey David Jacobson, Officer
- 31SEC EDGARMichael Gorenstein, Officer
- 32
- 33SEC EDGARRobert Steven Rosenheck, Officer
- 34SEC EDGARXiu Ming Shum, Officer
- 35
- 36SEC EDGARDominik Meier, Board member
- 37SEC EDGARElizabeth Seegar, Board member
- 38
- 39SEC EDGARHeather A. Newman, Board member
- 40
- 41SEC EDGARBruce Allen Gates, Board member
- 42SEC EDGARJames Daniel Rudyk, Board member
- 43SEC EDGARJason Marc Adler, Board member
- 44SEC EDGARJody L. Begley, Board member
- 45SEC EDGARMurray R. Garnick, Board member